Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 132, Issue 23
December 6 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

PLATELETS AND THROMBOPOIESIS
Natural, not immune; classical, not alternative
Theodore E. Warkentin
View Articletitled, Natural, not immune; classical, not alternative
CLINICAL TRIALS AND OBSERVATIONS
DUO delivers for duvelisib
Clinical Trials & Observations
Jennifer R. Brown
View Articletitled, DUO delivers for duvelisib
Lymphoid Neoplasia
How deep is the myeloma iceberg?
Jesús F. San-Miguel,Bruno Paiva
View Articletitled, How deep is the myeloma iceberg?
MYELOID NEOPLASIA
CiTE antibody for AML
Michael P. Rettig,John F. DiPersio
View Articletitled, CiTE antibody for AML
PLATELETS AND THROMBOPOIESIS
TLT-1: please release me, let me go
Yotis A. Senis
View Articletitled, TLT-1: please release me, let me go
TRANSPLANTATION
Stool can soften GVHD
Mette D. Hazenberg
View Articletitled, Stool can soften GVHD

PLENARY PAPER

PLATELETS AND THROMBOPOIESIS
Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway
Sanjay Khandelwal,Joann Ravi,Lubica Rauova,Alexandra Johnson,Grace M. Lee,Jennifer B. Gilner,Sreenivasulu Gunti,Abner L. Notkins,Maragatha Kuchibhatla,Michael Frank,Mortimer Poncz,Douglas B. Cines,Gowthami M. Arepally
View Articletitled, Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway
Supplemental data

BLOOD SPOTLIGHT

Reversing anti–factor Xa agents and the unmet needs in trauma patients
Clinical Trials & Observations
Beverley J. Hunt,Matthew D. Neal,Jakob Stensballe
View Articletitled, Reversing anti–factor Xa agents and the unmet needs in trauma patients

CLINICAL TRIALS AND OBSERVATIONS

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Clinical Trials & Observations
Ian W. Flinn,Peter Hillmen,Marco Montillo,Zsolt Nagy,Árpád Illés,Gabriel Etienne,Julio Delgado,Bryone J. Kuss,Constantine S. Tam,Zoltán Gasztonyi,Fritz Offner,Scott Lunin,Francesco Bosch,Matthew S. Davids,Nicole Lamanna,Ulrich Jaeger,Paolo Ghia,Florence Cymbalista,Craig A. Portell,Alan P. Skarbnik,Amanda F. Cashen,David T. Weaver,Virginia M. Kelly,Barry Turnbull,Stephan Stilgenbauer
View Articletitled, The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Supplemental data

LYMPHOID NEOPLASIA

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Clinical Trials & Observations
Aurore Perrot,Valerie Lauwers-Cances,Jill Corre,Nelly Robillard,Cyrille Hulin,Marie-Lorraine Chretien,Thomas Dejoie,Sabrina Maheo,Anne-Marie Stoppa,Brigitte Pegourie,Lionel Karlin,Laurent Garderet,Bertrand Arnulf,Chantal Doyen,Nathalie Meuleman,Bruno Royer,Jean-Richard Eveillard,Lotfi Benboubker,Mamoun Dib,Olivier Decaux,Arnaud Jaccard,Karim Belhadj,Sabine Brechignac,Brigitte Kolb,Cecile Fohrer,Mohamad Mohty,Margaret Macro,Paul G. Richardson,Victoria Carlton,Martin Moorhead,Tom Willis,Malek Faham,Kenneth C. Anderson,Jean-Luc Harousseau,Xavier Leleu,Thierry Facon,Philippe Moreau,Michel Attal,Hervé Avet-Loiseau,Nikhil Munshi
View Articletitled, Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma
Supplemental data
Subclonal TP53 copy number is associated with prognosis in multiple myeloma
Clinical Trials & Observations Brief Report
Vallari Shah,David C. Johnson,Amy L. Sherborne,Sidra Ellis,Frances M. Aldridge,Julie Howard-Reeves,Farzana Begum,Amy Price,Jack Kendall,Laura Chiecchio,Suvi Savola,Matthew W. Jenner,Mark T. Drayson,Roger G. Owen,Walter M. Gregory,Gareth J. Morgan,Faith E. Davies,Richard S. Houlston,Gordon Cook,David A. Cairns,Graham Jackson,Martin F. Kaiser,on behalf of the National Cancer Research Institute Haematology Clinical Studies Group
View Articletitled, Subclonal <em>TP53</em> copy number is associated with prognosis in multiple myeloma
Supplemental data

MYELOID NEOPLASIA

Bcor insufficiency promotes initiation and progression of myelodysplastic syndrome
Shiro Tara,Yusuke Isshiki,Yaeko Nakajima-Takagi,Motohiko Oshima,Kazumasa Aoyama,Tomoyuki Tanaka,Daisuke Shinoda,Shuhei Koide,Atsunori Saraya,Satoru Miyagi,Ichiro Manabe,Hirotaka Matsui,Haruhiko Koseki,Vivian J. Bardwell,Atsushi Iwama
View Articletitled, <em>Bcor</em> insufficiency promotes initiation and progression of myelodysplastic syndrome
Supplemental data
Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
Monika Herrmann,Christina Krupka,Katrin Deiser,Bettina Brauchle,Anetta Marcinek,Ana Ogrinc Wagner,Felicitas Rataj,Ralph Mocikat,Klaus H. Metzeler,Karsten Spiekermann,Sebastian Kobold,Nadja C. Fenn,Karl-Peter Hopfner,Marion Subklewe
View Articletitled, Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
Supplemental data

PLATELETS AND THROMBOPOIESIS

Platelet-derived TLT-1 is a prognostic indicator in ALI/ARDS and prevents tissue damage in the lungs in a mouse model
Jessica Morales-Ortíz,Victoria Deal,Fiorella Reyes,Gerónimo Maldonado-Martínez,Nahomy Ledesma,Franklin Staback,Cheyanne Croft,Amanda Pacheco,Humberto Ortiz-Zuazaga,C. Christian Yost,Jesse W. Rowley,Bismark Madera,Alex St. John,Junmei Chen,Jose Lopez,Matthew T. Rondina,Robert Hunter,Angelia Gibson,A. Valance Washington
View Articletitled, Platelet-derived TLT-1 is a prognostic indicator in ALI/ARDS and prevents tissue damage in the lungs in a mouse model
Supplemental data

TRANSPLANTATION

Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease
Alyson Swimm,Cynthia R. Giver,Zachariah DeFilipp,Sravanti Rangaraju,Akshay Sharma,Alina Ulezko Antonova,Robert Sonowal,Christopher Capaldo,Domonica Powell,Muna Qayed,Daniel Kalman,Edmund K. Waller
View Articletitled, Indoles derived from intestinal microbiota act via type I interferon signaling to limit graft-versus-host disease
Supplemental data

LETTER TO BLOOD

FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia
Jingliao Zhang,Yingchi Zhang,Man Zhang,Chao Liu,Xiaoming Liu,Jie Yin,Peng Wu,Xiaojuan Chen,Wenyu Yang,Li Zhang,Ye Guo,Yao Zou,Yumei Chen,Youjia Cao,Tao Cheng,Xiaofan Zhu
View Articletitled, FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia
Supplemental data

BLOOD WORK

Extensive Kaposi sarcoma infiltration in bone marrow in a patient with HIV
Kirill Lyapichev,Shaoying Li
View Articletitled, Extensive Kaposi sarcoma infiltration in bone marrow in a patient with HIV

ERRATA

Young K, Conley B, Romero D, et al. BMP9 regulates endoglin-dependent chemokine responses in endothelial cells. Blood. 2012;120(20):4263-4273.
View Articletitled, Young K, Conley B, Romero D, et al. BMP9 regulates endoglin-dependent chemokine responses in endothelial cells. <em>Blood</em>. 2012;120(20):4263-4273.
Scarfò I, Ormhøj M, Frigault MJ, et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018;132(14):1495-1506.
View Articletitled, Scarfò I, Ormhøj M, Frigault MJ, et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. <em>Blood</em>. 2018;132(14):1495-1506.
Schuetz C, Neven B, Dvorak CC, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood. 2014;123(2):281-289.
View Articletitled, Schuetz C, Neven B, Dvorak CC, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. <em>Blood</em>. 2014;123(2):281-289.
All Issues

Advertisement intended for health care professionals

Preclinical efficacy of potent and selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias
Genotype-Phenotype Correlations in Chronic Granulomatous Disease: Insights From a Large National Cohort
GVHD targets organoid-forming bile duct stem cells via a TGF-β-dependent manner
Quadriparesis and paraparesis following chimeric antigen receptor T-cell (CART) therapy in children and adolescents
How I Treat on Infant Acute Lymphoblastic Leukemia

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals